Chimeric Antigen Receptor Design for Enhanced CAR-T Cell Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies for cancer treatment face limitations in expression rates and therapeutic efficacy due to the lack of effective costimulatory domains and antigen binding domains, leading to short duration and limited effectiveness in targeting specific cancer cells.
Innovation Solution
A chimeric antigen receptor (CAR) is developed with a specific antigen binding domain, a hinge region, a transmembrane domain, and a cytoplasmic signaling domain, including a costimulatory domain composed of mutated CD28 or TNFRSF9, and additional glycines between the antigen binding domain and the hinge region, enhancing expression and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If early stage CAR-T cells (1st generation) using only CD3ζ as signaling domain are used, then the structure is simple, but the therapeutic effect is insignificant and duration time is short
Solution Approach 1:
The patent combines multiple functional domains (CD3ζ signaling domain, costimulatory domains CD28 and/or CD137, and antigen binding domain) into a single chimeric antigen receptor structure. This merging of previously separate components into one integrated CAR construct resolves the contradiction by achieving both structural organization and enhanced therapeutic effect with extended duration.
Solution Approach 2:
The CAR construct uses composite functional elements from different sources: human CD3ζ signaling domain, human costimulatory domains (CD28, CD137), and variable regions from mouse or human antibodies. This composite structure integrates multiple biological functions into one receptor, simultaneously achieving structural coherence and improved therapeutic reliability.
2Productivity
If 2nd generation CAR-T cells combining costimulatory domain (CD28 or CD137) and CD3ζ are produced, then the number of CAR-T cells increases significantly, but the expression rate and therapeutic efficacy are still limited
Solution Approach 1:
The patent optimizes the CAR structure by selecting specific components: CD3ζ signaling domain from normal human cells (with extra glutamine) rather than from Jurkat T cells, and incorporating both CD28 and CD137 costimulatory domains. These parameter changes in domain selection and combination improve both expression rate and therapeutic efficacy simultaneously.
Solution Approach 2:
The patent applies local quality optimization by using a hinge region derived from human CD8α chain with specific amino acid sequence, and a transmembrane domain from human CD3ε chain. These locally optimized components ensure proper receptor positioning and signaling while enhancing overall therapeutic efficacy and expression.
3Measurement precision
If CAR-T cells are designed to target specific cancer cell surface antigens, then the specificity of cancer cell targeting is improved, but the expression rate remains insufficient
Solution Approach 1:
The CAR is segmented into distinct functional modules: antigen binding domain (scFv), hinge region, transmembrane domain, costimulatory domains, and signaling domain. This segmentation allows each module to be independently optimized for its specific function while maintaining overall expression efficiency and cancer cell targeting specificity.
Solution Approach 2:
The hinge region acts as an intermediary component connecting the antigen binding domain to the transmembrane and signaling domains. This intermediary element facilitates proper folding and expression of the entire CAR construct while maintaining the specificity of antigen binding, thus resolving the contradiction between targeting precision and expression rate.
Data Source
AI summary
Disclosed is a chimeric antigen receptor comprising an antigen binding domain; a hinge region; a transmembrane domain; a costimulatory domain; and a cytoplasmic signaling domain.